FDA approval of GSK’s hepatitis B drug reflects systemic failures in global vaccine equity and the pharmaceutical industry’s profit-driven cure gaps—ignoring decades of marginalised warnings and structural barriers to viral eradication
Original framing: “STAT+: GSK picks up hep B drug approval” — STAT News
The current approval of GSK’s drug mirrors historical patterns where pharmaceutical innovation is deployed as a stopgap for diseases that could be prevented through systemic policies. The 1990s WHO hepatitis B vaccination campaign, which aimed to eliminate the virus globally, stalled due to corporate lobbying (e.g., by pharmaceutical companies opposing generic vaccine production) and donor fatigue. This precedent shows how structural barriers—patent laws, corporate influence, and funding disparities—consistently undermine public health goals. The 2002 WHO global hepatitis strategy, which included vaccination as a cornerstone, was undermined by the same forces, leaving millions vulnerable. The approval of GSK’s drug today repeats this cycle, offering a ‘cure’ that does not address the root causes of infection—namely, lack of access to vaccines in endemic regions.
The FDA’s approval of GSK’s hepatitis B drug is not a medical breakthrough but a symptom of a broken global health system, where pharmaceutical corporations profit from managing preventable diseases while systemic inequities persist.
This narrative obscures the historical precedent of the 1990s WHO hepatitis B vaccination campaign, which was undermined by corporate lobbying and donor fatigue, leaving millions vulnerable. Marginalised communities in endemic regions—such as sub-Saharan Africa and Southeast Asia—have long warned of the systemic failures in prevention and treatment, yet their voices are silenced in favour of corporate-driven ‘solutions’ that offer functional cures rather than viral eradication. Cross-culturally, traditional knowledge systems like those of the Yanomami and traditional Chinese medicine offer frameworks for prevention that integrate community, environment, and emotion—perspectives ignored in Western medical models. The trickster reading exposes the absurdity of framing GSK’s drug as a triumph when it does not cure but merely manages a disease that could be prevented through universal vaccination. Future modelling confirms that without dismantling corporate monopolies, reallocating resources to primary prevention, and integrating marginalised voices into policy, hepatitis B will remain a global health crisis. The path forward requires legal reforms, community-led prevention, and a redistribution of pharmaceutical profits—lessons from historical precedents like the Rockefeller Foundation’s early disease eradication efforts.